entertainment -WSS

entertainment

author：comprehensive 2025-09-30 12:11:28 - browse：67573

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

WSS

The Affordable Care Act has saved billions in health care costs

New England Journal of Medicine addresses racist history, slavery

Why you shouldn’t ask, “What country has the best health care?”

Merck, Johnson & Johnson CEOs will testify on high drug prices

Medicare Advantage insurers face 0.2% cut to 2025 payments

Syphilis numbers in the United States reach record heights

hotspot

entertainment

leisure time

23andMe had bad news about my health. I wish a person had delivered it

New Medicare drug pricing powers could soon be upended in court

Hollywood unions extend contract negotiations for actors

Zyn nicotine pouches become unlikely player in latest culture war

In age of alternative facts, a scholarly course on calling out crap

Designating disabled people as health disparity population is crucial

Continuity nursing helped my family in our darkest PICU moments

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Investment in vaccine development is lagging, report finds

hotspot

Medicare drug price negotiation legal challenge met with skepticism

Bernie Sanders is gearing up to subpoena pharma CEOs

Philips to halt sales of sleep apnea machines in U.S.

New menopause drug shows promise in relief for hot flashes

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

The SUPPORT Act is critical to fighting the opioid crisis

focus

hotspot

focus

leisure time